United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
| العنوان: | United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates |
|---|---|
| المؤلفون: | S. Duncil, R. Baumhefner, V. Gausche, L. Tvardek, G. Shifroni, E. Cerreta, S. Remo, J. H. Parnell, D. Lefkowitz, S. J. Bird, L. Needham, B. Borowski, M. Shepard, Y. Stark, S. Craig, L. Pardo, T. Vollmer, E. Katz, G. W. Ellison, C Jr Bever, A. C. Tselis, R. Grossman, P. M. Colletti, S. R. Schwid, I. Pinchasi, M. Singh, Staley A. Brod, W. Badger, Andrew D. Goodman, J. B. Guarnaccia, A. Gudusky, H. Panitch, M. A. Burns, J. Tsuruda, Jerry S. Wolinsky, J. W. Rose, D. Lisak, M. Gorbova, C. J. Becker, L. P. Weiner, E. W C Kwok, Dennis L. Kolson, B. Peters, C. Kawai, J. W. Lindsey, N. Carr, I. Vainrub, R. Misnick, K. McCarthy, R. Lewis, M. D. Petrie, J. Flemming, M. Viswanathan, C. Halvorson, K. P. Johnson, P. Turski, G. Sze, O. Khan, B. R. Brooks, D. Ladkani, D. Pfohl, A. Wallace, K. Martin, A. A. Pruitt, Francisco Gonzalez-Scarano, Ponnada A. Narayana, J. Kamholtz, R. Padilla, R. P. Lisak, L. Mannon, S. Kadosh, C. C. Ford, K. Conway, G. Hunter, S. Bhat, S. Jalbut, L. Medina, L. Rosner, L. W. Myers, G. Moore, J. B. Burns, S. Sinha, E. Greinel, J. Garbern, D. A. Shrier, M. Boykins, J. R. Bentson, N. Kachuck, M. Nessaiver |
| المصدر: | Multiple Sclerosis. 7:33-41 |
| بيانات النشر: | SAGE Publications, 2001. |
| سنة النشر: | 2001 |
| مصطلحات موضوعية: | medicine.medical_specialty, Randomization, medicine.diagnostic_test, business.industry, Multiple sclerosis, Copolymer I, Magnetic resonance imaging, medicine.disease, Placebo, Central nervous system disease, Clinical trial, Neurology, Internal medicine, medicine, Neurology (clinical), Glatiramer acetate, business, Nuclear medicine, medicine.drug |
| الوصف: | After the placebo-controlled extension of the pivotal US trial of glatiramer acetate for the treatment of relapsing multiple sclerosis ended, 208 participants entered an open-label, long-term treatment protocol. Magnetic resonance imaging (MRI) was added to the planned evaluations of these subjects to determine the consequences of long-term treatment on MRI-defined pathology and evaluate its clinical correlates. Of the 147 subjects that remained on long-term follow-up, adequate images were obtained on 135 for quantitative MRI analysis. The initial imaging sessions were performed between June 1998 and January 1999 at 2447+61 days (mean+standard deviation) after the subject's original randomization. Clinical data from a preplanned clinical visit were matched to MRI within 3+51 days. At imaging, 66 patients originally randomized to placebo (oPBO) in the pivotal trial had received glatiramer acetate for 1476+63 days, and 69 randomized to active treatment with glatiramer acetate (oGA) were on drug for 2433+59 ... |
| تدمد: | 1477-0970 1352-4585 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::a0a63205d214a1f405d85fd63875403c https://doi.org/10.1191/135245801667520627 |
| رقم الأكسشن: | edsair.doi...........a0a63205d214a1f405d85fd63875403c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14770970 13524585 |
|---|